Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$27,000.00

Combatting Antibiotic Resistance with Variable Lymphocyte Receptor B Antibodies

EF 2024-25

Résumé
The aim of this proposal is to develop a novel class of oral therapeutic to bacterial infection that may serve as an antibiotic alternative. A potential non-conventional treatment utilizes the variable lymphocyte receptor B (VLRB) antibody, which is an immunological protein produced by a jawless freshwater fish; the sea lamprey. VLRBs can be advantageous as an oral pharmaceutical agent due to their high affinity and selectivity to a specified target, as well as their extreme robustness in the harsh conditions of the gastrointestinal tract. As such, generating VLRBs that target bacterial virulence factors (VFs) may significantly interfere with the pathogenesis of adverse bacterium and expand our medical options.My proposal will focus on the preliminary stages of developing a VLRB-based oral therapeutic for bacterial infection. The pathogen I will be targeting is adherent invasive Escherichia Coli, which is largely responsible for causing Inflammatory Bowel Disorders such as Crohn's Disease. I will generate a panel of VLRB antibodies that target FimH, a crucial VF that facilitates the adhesion of AIEC to intestinal epithelial cells. FimH will be expressed and purified to immunize sea lamprey larvae with. Subsequently, VLRB clones that target successfully FimH will be isolated according to our lab's pre-established protocol. These clones will be fine-tuned to have higher affinity for FimH through an error prone polymerase chain reaction. Future experiments may utilize these anti-FimH VLRBs in AIEC murine models to assess their efficacyin vivo.The need to develop non-conventional treatments for bacterial infection is becoming extremely significant due to emerging antimicrobial resistance; highlighting the importance of VLRBs.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
529908
Name
Lau Angelica S
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Combatting Antibiotic Resistance with Variable Lymphocyte Receptor B Antibodies
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adherent Invasive Escherichia Coli; Crohn'S Disease; Fimh; Gastrointestinal; Sea Lamprey; Variable Lymphocyte Receptor B Antibody; Virulence Factor
Abstract
The aim of this proposal is to develop a novel class of oral therapeutic to bacterial infection that may serve as an antibiotic alternative. A potential non-conventional treatment utilizes the variable lymphocyte receptor B (VLRB) antibody, which is an immunological protein produced by a jawless freshwater fish; the sea lamprey. VLRBs can be advantageous as an oral pharmaceutical agent due to their high affinity and selectivity to a specified target, as well as their extreme robustness in the harsh conditions of the gastrointestinal tract. As such, generating VLRBs that target bacterial virulence factors (VFs) may significantly interfere with the pathogenesis of adverse bacterium and expand our medical options.My proposal will focus on the preliminary stages of developing a VLRB-based oral therapeutic for bacterial infection. The pathogen I will be targeting is adherent invasive Escherichia Coli, which is largely responsible for causing Inflammatory Bowel Disorders such as Crohn's Disease. I will generate a panel of VLRB antibodies that target FimH, a crucial VF that facilitates the adhesion of AIEC to intestinal epithelial cells. FimH will be expressed and purified to immunize sea lamprey larvae with. Subsequently, VLRB clones that target successfully FimH will be isolated according to our lab's pre-established protocol. These clones will be fine-tuned to have higher affinity for FimH through an error prone polymerase chain reaction. Future experiments may utilize these anti-FimH VLRBs in AIEC murine models to assess their efficacyin vivo.The need to develop non-conventional treatments for bacterial infection is becoming extremely significant due to emerging antimicrobial resistance; highlighting the importance of VLRBs.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lau, Angelica S
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~